title: Mitoxantrone--a useful palliative therapy in advanced breast cancer.
abstract: We have treated 76 patients with advanced breast cancer with single-agent mitoxantrone: all had previously received hormone therapy and 30 patients had also received prior chemotherapy. The overall response rate at 6 months was 15%, with a further 22% having static disease. Responding and static patients had similar survival curves and were grouped together as patients with "stable disease." Patients with stable disease had a significantly longer survival than patients with progressive disease (p less than 0.001); the median difference in survival was 9 months.
authors: Department of Surgery, City Hospital, Nottingham, England.
authors: J F
authors: JF
authors: Robertson
authors: M R
authors: MR
authors: Williams
authors: J H
authors: JH
authors: Todd
authors: R W
authors: RW
authors: Blamey
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D008942:Mitoxantrone / Q000009:adverse effects / Q000627:therapeutic use*; D010166:Palliative Care
chemical_list: D008942:Mitoxantrone